Search

Displaying results 681 - 690 of 5896 in total
  1. Drug

    Segesterone acetate

    go.drugbank.com/drugs/DB14583
    Approved

    In animal studies, segesterone acetate was shown to be one of the most potent progestins [A37090]. It mediates progestational activity 100 times higher than that of [progesterone] [A37092]. … Segesterone acetate binds selectively to progesterone receptors and not androgen receptors [A37083].

  2. Drug

    Cobamamide

    go.drugbank.com/drugs/DB11191
    ApprovedNutraceutical

    Cobamamide is one of the active forms of vitamin B12 that is also known as _adenosylcobalamin_ or _dibencozide_. … Vitamin B12 (cyancobalamin, Cbl) has two active co-enzyme forms, _methylcobalamin (MeCbl)_ and _adenosylcobalamin (AdCbl)_.

    Products: Co B12
  3. Drug

    Ziftomenib

    go.drugbank.com/drugs/DB17171
    ApprovedInvestigational

    [A274738] This drug was approved by the FDA on November 13th, 2025, for the treatment of relapsed or refractory acute myeloid leukemia (AML) in adults with a susceptible NPM1 mutation who have no satisfactory

    Synonyms: Menin-mll interaction inhibitor ko 539
  4. Drug

    Chlorpromazine

    go.drugbank.com/drugs/DB00477
    ApprovedInvestigationalVet approved

    Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  5. Drug

    Allogeneic processed thymus tissue

    go.drugbank.com/drugs/DB16736
    Approved

    [A239814] On October 8, 2021, FDA approved allogeneic processed thymus tissue-agdc, under the market name RETHYMIC, as a one-time regenerative tissue-based therapy for immune reconstitution in pediatric … [L38929] Congenital athymia is a rare condition that leads to the absence of a thymus at birth and a high premature mortality rate, with patients typically dying by age two or three.

  6. Drug

    Trastuzumab emtansine

    go.drugbank.com/drugs/DB05773
    ApprovedInvestigational

    T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-microtubule agent, DM1 (a maytansine derivative)--to produce cell cycle arrest and apoptosis. … The FDA label has two precautions. First that trastuzumab emtansine and trastuzumab cannot be interchanged.

  7. Drug

    Pectin

    go.drugbank.com/drugs/DB11158
    ApprovedInvestigationalVet approved

    This status allows pectin to be used with no limitations.[L1960]

    Mixtures: Kaolin Mixture W Pectin Nf, OPTAZOL-KO
  8. Drug

    Casirivimab

    go.drugbank.com/drugs/DB15941
    ApprovedInvestigational

    [L23539] This drug is a combination of antibodies derived from humanized VelocImmune® mice in addition to blood samples from patients who have recovered from COVID-19. … [A224429] These antibodies have been formulated to bind to multiple locations on the SARS-COV-2 spike protein, preventing viral escape.

  9. Drug

    Prucalopride

    go.drugbank.com/drugs/DB06480
    ApprovedInvestigational

    [A37348] The high selectivity of prucalopride allowed further development as it prevented the cardiac adverse reactions observed due to non-target effects of precedent therapies.

  10. Drug

    Oxybuprocaine

    go.drugbank.com/drugs/DB00892
    ApprovedInvestigational

    Oxybuprocaine binds to sodium channels and reversibly stabilizes the neuronal membrane which decreases its permeability to sodium ions.